Literature DB >> 21922133

Clonal cytogenetic progression within intratumorally heterogeneous meningiomas predicts tumor recurrence.

Steffi Urbschat1, Jörg Rahnenführer, Wolfram Henn, Wolfgang Feiden, Silke Wemmert, Stefan Linsler, Klaus D Zang, Joachim Oertel, Ralf Ketter.   

Abstract

Meningiomas arise from the coverings of the brain or the spinal cord. They are mostly benign and can be surgically cured. However, in approximately 5% of the cases, they turn into malignant forms with aggressive clinical behavior and increased risk of tumor recurrence. Cytogenetically meningiomas are well characterized, with normal karyotype or monosomy of chromosome 22 in most tumors and clinically relevant secondary losses of other autosomes and sex chromosomes in a subset of anaplastic tumors. Statistical analyses were performed for 1064 karyotypes derived from 661 meningiomas with respect to progression, and recurrence of the tumor. The order of accumulating genetic aberrations has previously been biostatistically estimated with oncogenetic tree models, and a genetic progression score derived from these models was shown to be predictive for tumor recurrence. Although more homogeneous than other cancer types, meningiomas show considerable intratumoral cytogenetic heterogeneity, particularly in their anaplastic form. We observed different cytogenetic patterns in tumor cells of 224 out of 661 (33.4%) meningiomas. The present study demonstrates that it is not sufficient to consider only the most frequent cytogenetic pattern observed in a sufficient set of cells derived from the same tumor. Even a single cell with more advanced genetic progression may start a clone and indicates also clinical progression. Cox regression analysis reveals that the clone with most advanced progression is a leading marker for recurrence in meningiomas. The aim of this study was the analysis of genetic heterogeneity on single cell basis. Further we investigated if there is a substantial correlation between the intratumoral heterogeneity of a given meningioma and its recurrence risk. We were able to show that the selection of single genetically advanced cells improves the prediction of clinical meningioma progression in a more precise manner.

Entities:  

Mesh:

Year:  2011        PMID: 21922133     DOI: 10.3892/ijo.2011.1199

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  13 in total

Review 1.  The evolution of tumour phylogenetics: principles and practice.

Authors:  Russell Schwartz; Alejandro A Schäffer
Journal:  Nat Rev Genet       Date:  2017-02-13       Impact factor: 53.242

2.  Immunohistochemical characterization of brain-invasive meningiomas.

Authors:  Thomas Backer-Grøndahl; Bjørnar H Moen; Magnus B Arnli; Kathrin Torseth; Sverre H Torp
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

3.  Proposal for a new risk stratification classification for meningioma based on patient age, WHO tumor grade, size, localization, and karyotype.

Authors:  Patrícia Henriques Domingues; Pablo Sousa; Álvaro Otero; Jesus Maria Gonçalves; Laura Ruiz; Catarina de Oliveira; Maria Celeste Lopes; Alberto Orfao; Maria Dolores Tabernero
Journal:  Neuro Oncol       Date:  2014-02-16       Impact factor: 12.300

4.  Inferring models of multiscale copy number evolution for single-tumor phylogenetics.

Authors:  Salim Akhter Chowdhury; E Michael Gertz; Darawalee Wangsa; Kerstin Heselmeyer-Haddad; Thomas Ried; Alejandro A Schäffer; Russell Schwartz
Journal:  Bioinformatics       Date:  2015-06-15       Impact factor: 6.937

5.  Development of patient-derived xenograft models from a spontaneously immortal low-grade meningioma cell line, KCI-MENG1.

Authors:  Sharon K Michelhaugh; Anthony R Guastella; Kaushik Varadarajan; Neil V Klinger; Prahlad Parajuli; Aamir Ahmad; Seema Sethi; Amro Aboukameel; Sam Kiousis; Ian M Zitron; Salah A Ebrahim; Lisa A Polin; Fazlul H Sarkar; Aliccia Bollig-Fischer; Sandeep Mittal
Journal:  J Transl Med       Date:  2015-07-15       Impact factor: 5.531

Review 6.  Genetic/molecular alterations of meningiomas and the signaling pathways targeted.

Authors:  Patrícia Domingues; María González-Tablas; Álvaro Otero; Daniel Pascual; Laura Ruiz; David Miranda; Pablo Sousa; Jesús María Gonçalves; María Celeste Lopes; Alberto Orfao; María Dolores Tabernero
Journal:  Oncotarget       Date:  2015-05-10

7.  Establishment of a molecular cytogenetic analysis for native tumor tissue of meningiomas-suitable for clinical application.

Authors:  Cornelia Lerner; Ralf Ketter; Stefan Linsler; Wolfram Henn; Joachim Oertel; Steffi Urbschat
Journal:  Mol Cytogenet       Date:  2014-02-05       Impact factor: 2.009

8.  Molecular biological determinations of meningioma progression and recurrence.

Authors:  Stefan Linsler; Dennis Kraemer; Christina Driess; Joachim Oertel; Kai Kammers; Jörg Rahnenführer; Ralf Ketter; Steffi Urbschat
Journal:  PLoS One       Date:  2014-04-10       Impact factor: 3.240

9.  Algorithms to model single gene, single chromosome, and whole genome copy number changes jointly in tumor phylogenetics.

Authors:  Salim Akhter Chowdhury; Stanley E Shackney; Kerstin Heselmeyer-Haddad; Thomas Ried; Alejandro A Schäffer; Russell Schwartz
Journal:  PLoS Comput Biol       Date:  2014-07-31       Impact factor: 4.475

10.  Variable selection for disease progression models: methods for oncogenetic trees and application to cancer and HIV.

Authors:  Katrin Hainke; Sebastian Szugat; Roland Fried; Jörg Rahnenführer
Journal:  BMC Bioinformatics       Date:  2017-08-01       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.